IDiyas

For the Inventor, By the Inventor

Takarazuka, Japan

Shoji Kishimoto

USPTO Granted Patents = 26

Average Co-Inventor Count = 2.8

ph-index = 14

Forward Citations = 770(Granted Patents)


Location History:

  • Hyogo, JP (1985 - 1990)
  • Takarazuka, both of, JP (1993)
  • Takarazuka, JP (1982 - 1997)

Company Filing History:

goldMedal26 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1982-1997

Loading Chart...
26 patents (USPTO):Explore Patents
1. 5698586 - Angiogenesis inhibitory agent (1997-12-16),
2. 5288722 - 6-amino-6-desoxyfumagillols, production and use thereof (1994-02-22),
3. 5204345 - 6-epifumagillols and the pharmaceutical use thereof (1993-04-20),
4. 5196406 - Cyclodextrin complex of fumagillin derivative (1993-03-23),
5. 5180738 - Fumagillol derivatives and pharmaceutical compositions thereof (1993-01-19),
6. 5180735 - Cyclohexanol derivatives, production and use thereof (1993-01-19),
7. 5166172 - Fumagillol derivatives and pharmaceutical compositions thereof (1992-11-24),
8. 5164410 - Fumagillol derivatives and pharmaceutical compositions thereof (1992-11-17),
9. 4971963 - Cephem compounds, and use (1990-11-20),
10. 4942159 - Cephem compounds, their production and use (1990-07-17),
11. 4921851 - Cephem compounds, their production and use (1990-05-01),
12. 4833134 - Cephem compounds (1989-05-23),
13. 4826834 - Cephem compounds (1989-05-02),
14. 4822788 - 1-sulfo-2-oxozetidine derivatives and their product ion (1989-04-18),
15. 4794108 - 1-carboxymethoxy acetidinones and their production (1988-12-27),

Title: Innovations in Angiogenesis Research by Shoji Kishimoto

Introduction

Shoji Kishimoto, a prominent inventor based in Takarazuka, Japan, has made significant contributions to the field of medical research, focusing on angiogenesis. With an impressive portfolio comprising 26 patents, Kishimoto's work primarily revolves around novel compounds that play crucial roles in inhibiting abnormal blood vessel growth, relevant for various medical conditions.

Latest Patents

Kishimoto's recent patents highlight his innovative approach to addressing neovascularization-related diseases. One notable invention is the angiogenesis inhibitory agent—O-substituted fumagillol derivatives and its salts, which exhibit strong angiogenesis inhibiting activity beneficial for both prophylaxis and treatment of related medical conditions. Another significant patent revolves around 6-amino-6-desoxyfumagillols, a compound shown to possess angiogenesis inhibiting, cell-growth inhibiting, and immune reaction inhibiting activities, thus proving to be advantageous in medicinal applications.

Career Highlights

Working at Takeda Chemical Industries, Inc., Kishimoto has leveraged his expertise to develop transformative solutions in pharmaceuticals. His research not only emphasizes angiogenesis but also extends to various medical applications, showcasing his commitment to advancing healthcare.

Collaborations

Throughout his career, Kishimoto has collaborated with esteemed colleagues such as Michihiko Ochiai and Takeshi Fujita. These partnerships have enriched his research endeavors, leading to innovative breakthroughs in the understanding of angiogenesis and its implications in medical science.

Conclusion

Shoji Kishimoto's contributions to angiogenesis research underline his status as a leading inventor in the field. With a robust patent portfolio and impactful collaborations, his ongoing work continues to foster advancements in medical treatments, exemplifying the power of innovation in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…